Chu-Chi Lin
Overview
Explore the profile of Chu-Chi Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Chiu C, Wang C, Lin C, Shen C, Yao Y, et al.
Int J Nanomedicine
. 2025 Jan;
20:951-966.
PMID: 39867314
Background: In clinical practice, imiquimod is used to treat Human Papillomavirus (HPV)-related lesions, such as condyloma and Cervical Intraepithelial Neoplasia (CIN). Metronidazole is the most commonly prescribed antibiotic for bacterial...
2.
Anurogo D, Chen C, Lin C, Pawitan J, Qiu D, Qiu J
J Immunotoxicol
. 2024 Sep;
21(1):2400624.
PMID: 39319829
Infections caused by the influenza virus lead to both epidemic and pandemic outbreaks in humans and animals. Owing to their rapid production, safety, and stability, DNA vaccines represent a promising...
3.
Enhancing immunogenicity of HPV16 E DNA vaccine by conjugating codon-optimized GM-CSF to HPV16 E DNA
Chen Y, Lin C, Xie Y, Chen C, Qiu J
Taiwan J Obstet Gynecol
. 2021 Jul;
60(4):700-705.
PMID: 34247810
Objective: To generate immunity against human papillomavirus (HPV), the use of a recombinant DNA vaccine to carry an appropriate target gene is a promising and cost-effective approach. Granulocyte-macrophage colony-stimulating factor...
4.
Lin C, Chen C, Wang C, Hung S, Chung W
Expert Rev Clin Immunol
. 2020 Mar;
16(4):373-387.
PMID: 32154748
The clinical manifestations of cutaneous adverse drug reactions are variable with different severity. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs) majorly caused...
5.
Huang K, Hsu F, Qiu J, Chern G, Lee Y, Chang C, et al.
Sci Adv
. 2020 Jan;
6(3):eaax5032.
PMID: 31998834
While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader application of cancer immunotherapy. Here, we report...
6.
Sung Y, Jin P, Chu L, Hsu F, Wang M, Chang C, et al.
Nat Nanotechnol
. 2019 Nov;
14(12):1160-1169.
PMID: 31740794
Abnormal tumour vasculature has a significant impact on tumour progression and response to therapy. Nitric oxide (NO) regulates angiogenesis and maintains vascular homeostasis and, thus, can be delivered to normalize...
7.
Qiu J, Alson D, Lee T, Tsai C, Yu T, Chen Y, et al.
Cancers (Basel)
. 2019 Mar;
11(3).
PMID: 30875953
Ectopic expression of codon-modified granulocyte-macrophage colony-stimulating factor (cGM-CSF) in TC-1 cells (TC-1/cGM-CSF), a model cell line for human papillomavirus (HPV)-infected cervical cancer cells, increased the expression level of GM-CSF and...
8.
Kojima T, Lin C, Takayama S, Fan S
Chembiochem
. 2018 Nov;
20(2):270-275.
PMID: 30394637
Handling the aqueous two-phase systems (ATPSs) formed by liquid-liquid phase separation (LLPS) relies on the accurate construction of binodal curves and tie-lines, which delineate the polymer concentrations required for phase...
9.
Liu C, Chern G, Hsu F, Huang K, Sung Y, Huang H, et al.
Hepatology
. 2017 Sep;
67(3):899-913.
PMID: 28885731
Conclusion: TRAIL pDNA delivered by HCC-targeted LCPP NPs in combination with conventional sorafenib treatment attenuated HCC progression as well as liver fibrosis. Overall, our study presents an effective TRAIL-based cancer...
10.
Lin C, Tsai C, Lee J, Fang C, Chang K, Wong K, et al.
Vaccine
. 2015 Nov;
34(1):134-41.
PMID: 26546261
Granulocyte macrophage-colony stimulating factor (GM-CSF) is a potent immunomodulatory cytokine that is known to facilitate vaccine efficacy by promoting the development and prolongation of both humoral and cellular immunity. Here,...